$511.78
Value $107B
HCA and LLY stock compared: price, dividend, valuation and results, from SEC filings.
$511.78
Value $107B
$1,431.67
Value $1.35T
HCA Healthcare (HCA) has a market value of $107B and Eli Lilly and Company (LLY) $1.35T. Over the last year, with dividends, HCA moved +6.1% and LLY +42.9%. The P/E is 15.8 for HCA and 49.0 for LLY. Dividend yield: HCA 0.60%, LLY 0.44%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
HCA$107B
LLY$1.35T
LLY is 13 times HCA
Revenue, 12 months
HCA$78.7B
LLY$86.5B
LLY is 1.1 times HCA
Net income, 12 months
HCA$6.8B
LLY$27.6B
LLY is 4.1 times HCA
Operating margin
HCA–
LLY–
ROIC
HCA18.9%
LLY35.5%
16.6 points apart
P/E
HCA15.8
LLY49.0
LLY is 3.1 times HCA
Dividend yield
HCA0.6%
LLY0.4%
0.2 points apart
5-year return
HCA+112.1%
LLY+480.4%
368.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
HCA+112.1%
LLY+480.4%
| Period | HCAWith dividends | LLYWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +6.1%Price +5.4% | +42.9%Price +41.8% |
| 3 years since November 13, 2023 | +122.0%+30.4% a yearPrice +117.0% | +140.8%+34.0% a yearPrice +135.6% |
| 5 years since November 12, 2021 | +112.1%+16.2% a yearPrice +103.5% | +480.4%+42.2% a yearPrice +455.9% |
| 10 years since November 16, 2016 | +633.8%+22.1% a yearPrice +578.6% | +2,082.4%+36.1% a yearPrice +1,776.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
HCAHCA HealthcareLLYEli Lilly and Company
| Price | $511.78 | $1,431.67 |
|---|---|---|
| Market value | $107B | $1.35T |
| Enterprise value (EV) | $156B | $1.40T |
| P/E | 15.8 | 49.0 |
| P/E, 5-year median | 13.6 | 49.9 |
| P/B | – | 33.5 |
| EV/EBIT | 15.9 | 40.1 |
| Free cash flow yield | 5.6% | 1.5% |
| Revenue, 12 months | $78.7B | $86.5B |
|---|---|---|
| Net income, 12 months | $6.8B | $27.6B |
| Free cash flow, 12 months | $6.0B | $19.7B |
| Earnings per share, 12 months | $30.14 | $30.81 |
| Revenue growth, year on year | 7.1% | 44.7% |
| Revenue growth a year, past | +8.0%over 5 years | +21.6%over 5 years |
| EPS growth a year, past | +21.0%over 5 years | +27.6%over 5 years |
| Gross margin | – | 83.6% |
|---|---|---|
| Operating margin | – | – |
| Net margin | 8.6% | 31.9% |
| ROIC | 18.9% | 35.5% |
| ROE | – | 88.6% |
| Cash | $944M | $4.9B |
|---|---|---|
| Total debt | $52.4B | $49.5B |
| Net debt / EBITDA | 3.7 | 1.2 |
| Interest cover | 4.2× | 38.9× |
| Dividend yield | 0.6% | 0.4% |
|---|---|---|
| Dividend per share, 12 months | $3.06 | $6.34 |
| Dividend growth a year, past | – | +15.2%over 5 years |
| Buyback yield | 9.4% | 0.3% |
| Shareholder yield | 10.0% | 0.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.35T) is about 12.6 times HCA Healthcare ($107B), at today's prices.
Since November 16, 2016, HCA's price moved +578.6% and LLY's +1,776.1%. With dividends: HCA +633.8% (+22.1% a year), LLY +2,082.4% (+36.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.60% for HCA Healthcare and 0.44% for Eli Lilly and Company. Over the last twelve months they paid $3.06 and $6.34 per share.
At today's price, the P/E is 15.8 for HCA and 49.0 for LLY. The median of the last five years was 13.6 and 49.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 8.6% for HCA Healthcare and 31.9% for Eli Lilly and Company, and the operating margin – and –. Revenue was $78.7B and $86.5B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.